[go: up one dir, main page]

ATE324455T1 - Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie - Google Patents

Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie

Info

Publication number
ATE324455T1
ATE324455T1 AT98945090T AT98945090T ATE324455T1 AT E324455 T1 ATE324455 T1 AT E324455T1 AT 98945090 T AT98945090 T AT 98945090T AT 98945090 T AT98945090 T AT 98945090T AT E324455 T1 ATE324455 T1 AT E324455T1
Authority
AT
Austria
Prior art keywords
mhc class
lag
vaccination
adjuvants
ligands
Prior art date
Application number
AT98945090T
Other languages
English (en)
Inventor
Frederique Triebel
Original Assignee
Roussy Inst Gustave
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE324455T1 publication Critical patent/ATE324455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98945090T 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie ATE324455T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (de) 1997-07-25 1997-07-25 Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs

Publications (1)

Publication Number Publication Date
ATE324455T1 true ATE324455T1 (de) 2006-05-15

Family

ID=8229825

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98945090T ATE324455T1 (de) 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
AT06008545T ATE478956T1 (de) 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06008545T ATE478956T1 (de) 1997-07-25 1998-07-23 Verwendung von mhc klasse ii liganden (cd4 und lag-3) als adjuvans für impfungen und von lag-3 bei behandlung von krebs

Country Status (20)

Country Link
US (2) US6410509B1 (de)
EP (3) EP0893507A1 (de)
JP (1) JP4723722B2 (de)
KR (1) KR100603075B1 (de)
CN (1) CN1184320C (de)
AT (2) ATE324455T1 (de)
AU (1) AU753738B2 (de)
BR (1) BR9811037A (de)
CA (2) CA2732570C (de)
DE (2) DE69834330T2 (de)
DK (1) DK1002108T3 (de)
EA (3) EA005405B1 (de)
EE (1) EE200000039A (de)
ES (1) ES2262242T3 (de)
HK (1) HK1030014A1 (de)
IL (2) IL134212A0 (de)
NO (1) NO20000378D0 (de)
PT (1) PT1002108E (de)
UA (1) UA75322C2 (de)
WO (1) WO1999004810A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519779T1 (de) * 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
EP1596871A4 (de) 2003-02-28 2006-08-23 Drew M Pardoll T-zell-regulierung
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (de) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
EP2044949A1 (de) * 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
PL2638062T3 (pl) 2010-11-10 2018-11-30 Laboratorios Leti, S.L. Nowy adiuwant
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
ME03558B (de) 2014-03-14 2020-07-20 Novartis Ag Antikörpermoleküle gegen lag-3 und verwendungen davon
AU2015329070B2 (en) 2014-10-07 2018-11-22 Nec Corporation Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TW202115102A (zh) 2015-03-09 2021-04-16 日商賽多利克公司 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
TWI738646B (zh) 2015-04-07 2021-09-11 日商賽多利克公司 醫藥組成物
JP6925980B2 (ja) 2015-05-13 2021-08-25 アジェナス インコーポレイテッド がんの処置および予防のためのワクチン
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
WO2017046409A1 (en) 2015-09-18 2017-03-23 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
BR112019006075A2 (pt) 2016-10-11 2019-06-18 Cytlimic Inc medicamento
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
CA3114585A1 (en) * 2018-09-27 2020-04-02 Genocea Biosciences, Inc. Treatment methods
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
JPH03505039A (ja) * 1988-08-22 1991-11-07 アメリカ合衆国 可溶性ｃｄ４を発現するレトロウイルスベクター、エイズの遺伝子治療法
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
EP0681483B1 (de) * 1993-01-26 2005-08-24 The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) Zusammensetzungen und verfahren zur verabreichung von genetischem material
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
CN1110557C (zh) * 1994-05-06 2003-06-04 古斯达威罗斯研究所 Lag－3蛋白的可溶性多肽组分;生产方法、治疗组合物、抗独特型抗体
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
JP2001506122A (ja) * 1994-12-07 2001-05-15 エフ．ホフマン−ラ ロシュ アーゲー 免疫抑制作用を有するモノクローナル抗体断片
EP0800534A2 (de) * 1994-12-23 1997-10-15 Laboratoires Om S.A. Verwendung von mhc-ii bindeden und/oder imitierenden molekülen zur vorbeugung und/oder behandlung von entzündlichen krankheiten
EP0869803B1 (de) * 1995-12-28 2003-04-16 The Johns Hopkins University School Of Medicine Allogene parakrine cytokine tumor impfstoffe

Also Published As

Publication number Publication date
US7109026B2 (en) 2006-09-19
WO1999004810A3 (en) 1999-07-08
EP1698701B1 (de) 2010-08-25
AU753738B2 (en) 2002-10-24
DE69841866D1 (de) 2010-10-07
CA2732570C (en) 2014-11-18
NO20000378L (no) 2000-01-25
EA200200565A1 (ru) 2002-10-31
CN1184320C (zh) 2005-01-12
EA003740B1 (ru) 2003-08-28
KR100603075B1 (ko) 2006-07-20
BR9811037A (pt) 2000-08-01
US6410509B1 (en) 2002-06-25
EP1002108A2 (de) 2000-05-24
DK1002108T3 (da) 2006-08-21
WO1999004810A2 (en) 1999-02-04
KR20010021706A (ko) 2001-03-15
HK1030014A1 (en) 2001-04-20
EE200000039A (et) 2000-10-16
NO20000378D0 (no) 2000-01-25
US20020192195A1 (en) 2002-12-19
JP4723722B2 (ja) 2011-07-13
DE69834330D1 (de) 2006-06-01
EA005405B1 (ru) 2005-02-24
PT1002108E (pt) 2006-09-29
AU9254798A (en) 1999-02-16
DE69834330T2 (de) 2007-03-29
EA200000161A1 (ru) 2000-10-30
EP0893507A1 (de) 1999-01-27
EP1698701A1 (de) 2006-09-06
IL134212A0 (en) 2001-04-30
EA200300092A1 (ru) 2003-06-26
CA2293805A1 (en) 1999-02-04
CA2732570A1 (en) 1999-02-04
ATE478956T1 (de) 2010-09-15
CA2293805C (en) 2011-05-03
IL134212A (en) 2012-03-29
EP1002108B1 (de) 2006-04-26
JP2001510806A (ja) 2001-08-07
CN1265149A (zh) 2000-08-30
UA75322C2 (en) 2006-04-17
ES2262242T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE324455T1 (de) Verwendung von mhc klasse ii liganden als adjuvantien zur impfung und von lag-3 zur krebstherapie
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
TR200202231T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
NO983999D0 (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
WO2002072013A3 (en) Method of treating malignancies through induction of blood immune responses
ATE286914T1 (de) Verwendung von blockierenden anti-tsh-rezeptor- antikörpern bei der therapie von hyperthyreosen sowie monoklonale antikörper für eine solche verwendung
PT979093E (pt) Agente viral terapeutico que interrompe o desenvolvimento de tumores
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
DK0788355T3 (da) Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme
WO1999050289A3 (en) Transformation progression-related genes and their use
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
WO2003034069A3 (en) Tcmp 03 protein for use in cancer therapy
DE58904510D1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
ATE89727T1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1002108

Country of ref document: EP

EEIH Change in the person of patent owner